Avalo Therapeutics, Inc (AVTX) insider trading
Every open-market stock purchase and sale by Avalo Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Christopher Ryan Sullivan (CFO) and 2 others sold $2M in the last 90 days.
- Last insider buy: June Sherie Almenoff (Director), $6.5K, 23 months ago.
Last 12 months: insiders bought $0 (0 buys) and sold $8.5M (23 sales). Last close $12.26 on Oct 21, 2026.
Recent AVTX insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Sep 30, 2026 | Kevin Robert Lind (Insider) | Bought (not open market) | $16.6K |
| Sep 30, 2026 | Rita Jain (Insider) | Bought (not open market) | $16.2K |
| Sep 30, 2026 | Ron M Philip (Insider) | Bought (not open market) | $13.6K |
| Sep 16, 2026 | Christopher Ryan Sullivan (CFO) | Sold | $202K |
| Sep 16, 2026 | Christopher Ryan Sullivan (CFO) | Bought (not open market) | — |
| Sep 10, 2026 | Christopher Ryan Sullivan (CFO) | Sold | $179K |
| Sep 10, 2026 | Christopher Ryan Sullivan (CFO) | Bought (not open market) | — |
| Aug 28, 2026 | Mittie Doyle (C-suite exec) | Sold | $13.6K |
| Aug 28, 2026 | Mittie Doyle (C-suite exec) | Bought (not open market) | — |
| Aug 18, 2026 | Christopher Ryan Sullivan (CFO) | Sold | $622K |
| Aug 18, 2026 | Christopher Ryan Sullivan (CFO) | Bought (not open market) | — |
| Aug 17, 2026 | Christopher Ryan Sullivan (CFO) | Sold | $753K |
| Aug 17, 2026 | Christopher Ryan Sullivan (CFO) | Sold | $74.8K |
| Aug 17, 2026 | Mittie Doyle (C-suite exec) | Sold | $20K |
| Aug 17, 2026 | Christopher Ryan Sullivan (CFO) | Bought (not open market) | — |
| Aug 17, 2026 | Mittie Doyle (C-suite exec) | Bought (not open market) | — |
| Aug 17, 2026 | Christopher Ryan Sullivan (CFO) | Bought (not open market) | — |
| Aug 11, 2026 | Jennifer Riley (C-suite exec) | Sold | $52K |
| Aug 10, 2026 | Mittie Doyle (C-suite exec) | Sold | $13.6K |
| Aug 10, 2026 | Mittie Doyle (C-suite exec) | Bought (not open market) | — |
| Jul 27, 2026 | Mittie Doyle (C-suite exec) | Sold | $20K |
| Jul 27, 2026 | Mittie Doyle (C-suite exec) | Bought (not open market) | — |
| Jun 30, 2026 | Mittie Doyle (C-suite exec) | Sold | $93.1K |
| Jun 30, 2026 | Mittie Doyle (C-suite exec) | Bought (not open market) | $36.4K |
| Jun 30, 2026 | Kevin Robert Lind (Insider) | Bought (not open market) | $16.6K |
Who's trading AVTX
- Rita Jain, Insider: other filings, last Sep 30, 2026
- Ron M Philip, Insider: other filings, last Sep 30, 2026
- Kevin Robert Lind, Insider: other filings, last Sep 30, 2026
- Christopher Ryan Sullivan, CFO: sold $3.7M (17 sales), last Sep 16, 2026
- Mittie Doyle, C-suite exec: sold $3M (17 sales), last Aug 28, 2026
- Jennifer Riley, C-suite exec: sold $52K (1 sale), last Aug 11, 2026
- Paul Varki, C-suite exec: sold $1.5M (5 sales), last Jun 10, 2026
- Gilla Kaplan, Director: other filings, last Jun 2, 2026
- Michael Thomas Heffernan, Director: other filings, last Jun 2, 2026
- Aaron Kantoff, Director: other filings, last Jun 2, 2026
- Samantha Truex, Director: other filings, last Jun 2, 2026
- Garry Arthur Neil, CEO: other filings, last May 21, 2026
- Mitchell Chan, Director: sold $72.5K (1 sale), last May 6, 2026
- Jonathan Goldman, Director: sold $163K (2 sales), last Mar 28, 2026
- Taylor Boyd, C-suite exec: other filings, last Feb 26, 2026
Get free alerts when an insider at Avalo Therapeutics, Inc files a new trade →